All In Biotech

Drug Trial Radar · NCT07511127

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Patients With Refractory Cytomegalovirus Infection Following Allo-HSCT: a Prospective, Multicenter, Randomized, Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.

Conditions

  • Hematologic Malignancy

Interventions

  • MaribavirDrug

    During the treatment period, maribavir is administered orally at a dosage of 400 mg twice daily. Participants will be stratified by clinical trial and received oral medication for varying durations.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of recurrent CMV infectionTime frame: The primary endpoint is assessed 8 weeks after maribavir discontinuation following allo-HSCT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.